Global Visceral Leishmaniasis Treatment Market - 2023-2030

Global Visceral Leishmaniasis Treatment Market - 2023-2030

Global visceral leishmaniasis treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.

The global visceral leishmaniasis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Over 95% of cases of visceral leishmaniasis (VL), often known as kala-azar, are fatal if untreated. It is distinguished by irregular fever attacks, weight loss, spleen and liver enlargement, and anemia. Brazil, east Africa, and India account for the majority of instances.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or therapies and boost the global visceral leishmaniasis treatment market. The respective innovative products includes the use of novel treatments such as pentavalent antimonials for better management.

Market Dynamics: Drivers & Restraints

Growing collaborations and government initiatives

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for visceral leishmaniasis treatment owing to the positive outcomes in research. Various regulatory approvals for product launch among different countries will be a crucial factor driving the growth of the market.

On January 26, 2023, the previous agreement between the World Health Organization (WHO) and Gilead Sciences was extended through 2025 with the signing of another contract for the supply of AmBisome (liposomal amphotericin B injection) 304,700 vials for the management of visceral leishmaniasis in nations most affected by the disease.

The new three-year agreement (2023-2025), which is expected to cost $11.3 million, also includes financial support for better coverage, access, and therapy for visceral leishmaniasis-affected communities.

Furthermore, the rising utilization of novel therapies or drugs for the management of alpha-1 antitrypsin deficiency. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the Visceral Leishmaniasis Treatments market.

Side effects associated with the drugs

Rashes, hyperglycemia, hypomagnesemia, hypokalemia, diarrhea, vomiting, nausea, anemia, raised alkaline phosphatase, higher levels of urea nitrogen in blood, chills, raised creatinine, insomnia, and dyspnea are the most frequently reported adverse reactions with an incidence of >20% with AmBisome across all studies. Chills/rigors, nausea, fever, vomiting, tachycardia, hypertension, dyspnea, and hypoxia are among responses connected to infusions.

The administration of AmBisome has been linked to a few instances of flushing, back discomfort regardless of chest tightness, or chest pain; on occasion, this has become severe. Where these signs were observed, a reaction arose shortly after the infusion began and quickly subsided when it was stopped. When the infusion frequency is lowered, these symptoms normally do not return with consecutive doses and do not happen with every dose.

Segment Analysis

The global visceral leishmaniasis treatment market is segmented based on drug type, route of administration, end user and region.

Amphotericin B Liposomal segment accounted for approximately 39% of market share

Ambisome Injection is a member of the 'antifungal' drug class, which is used for the treatment of severe fungal infections including leishmaniasis. A fungal infection is a condition when fungi infect the tissue and attack it. Although fungi are frequently found in nature, they typically do not cause illnesses.

Some fungi, however, may infect a human if they have a weakened immune system. Amphotericin B, an ingredient in ambisome injection, kills fungus by rupturing their outer cell membrane. Since they inhibit the escape of cell contents and the entry of undesirable substances into the cells, the fungal cell walls are crucial for their survival.

On December 15, 2021, the US FDA has given its final approval to Sun Pharmaceutical Industries Limited's wholly-owned subsidiaries for its abbreviated new drug application (ANDA) for 50 mg/vial amphotericin b liposome generic version for Injection, Single-Dose Vial. AmBisome Liposome Injection, 50 mg/vial is used as the basis for the approval of the generic product.

AmBisome Liposome Injection, 50 mg/vial is used as the basis for the approval of the generic product. The US FDA has given Sun Pharma the classification of competitive generic therapy (CGT), and as the first generic approved, the company is entitled to CGT exclusivity of 180 days for the drug.

Geographical Penetration

North America accounted for around 35% of market share in 2022

Due to the rising need for visceral leishmaniasis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for visceral leishmaniasis treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of therapies for management, and increase in pharmaceutical or biotechnology business establishment across the region are also contributing to the growth of visceral leishmaniasis treatment market share of this region. The market in this area is growing as people become more aware of various novel innovative therapies such as amphotericin b liposomal. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global visceral leishmaniasis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for visceral leishmaniasis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating visceral leishmaniasis treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global visceral leishmaniasis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for visceral leishmaniasis treatment. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global visceral leishmaniasis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like antimicrobials and other programs for management of leishmaniasis.

Key Developments
• On March 30, 2023, for the purpose of treating cryptococcal meningitis and visceral leishmaniasis in low- and middle-income nations, Gilead Sciences, Inc. will recalculate the no-profit cost of AmBisome (amphotericin B liposome for injection 50mg/vial) for governments and other non-governmental health organizations serving the public sector. This modification is being made by Gilead to guarantee the long-term viability of the AmBisome supply for the firm's global access initiative in these nations.
• On September 29, 2022, The Drugs for Neglected Diseases initiative (DNDi), a non-profit medical research organization, and its collaborators conducted a trial in Eastern Africa that demonstrated the efficacy of a shorter, less toxic treatment for persons with visceral leishmaniasis. The novel therapy combines paromomycin (PM), an injectable antibiotic, with miltefosine (MF), the only oral medication available to treat leishmaniasis.

Competitive Landscape

The major global players in the market include Merck KGaA, PRG Pharma, LEXICARE PHARMA PVT. LTD., SanMak Pharmaceuticals Private Limited, Pfizer Inc., Avet Pharmaceuticals Inc., Profounda Pharmaceuticals,Knight Therapeutics Inc., Sun Pharmaceutical Industries Ltd. and Gilead Sciences, Inc..

Why Purchase the Report?
• To visualize the global visceral leishmaniasis treatment market segmentation based on drug type, route of administration, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of visceral leishmaniasis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global visceral leishmaniasis treatment market report would provide approximately 61 tables, 57 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies